NXTCEUR
Nextcure, Inc.
A clinical-stage biopharmaceutical company developing immunomedicines to treat cancer. Its investigational drugs aim to restore the body's natural immune defenses against tumors, with candidate therapies for lung, head and neck, and other solid tumors. Nextcure was founded in 2015 by Dr. Lieping Chen, the immunologist who discovered PD-L1 and helped pioneer the checkpoint inhibitor field, and its name reflects the goal of building next-generation cures by mapping how immune cells interact with cancer.
CUSIP: 65343E108HealthcareUS1 holder